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Previous studies on baseline pulmonary function testing (PFT) abnormalities in patients with inflammatory bowel 
disease (IBD) are conflicting because most of them have incorporated patients suffering from both ulcerative colitis 
(UC) and Crohn’s disease (CD). The aim of the study is to investigate whether any PFT abnormalities could be 
detected in a large group of IBD patients and whether there are differences between the two IBD entities. A total of 
132 patients, 47 with CD (mean age 35 years) and 85 with UC (mean age 40 years) were studied. Pulmonary function 
tests (PFTs), lung transfer factor for carbon monoxide (no,) were examined and compared with those of 36 
healthy controls. No significant difference of mean values of spirometric indices, no0 and ABG was found between 
the two groups of patients and controls, or between patients with CD and UC. However, nine (19%) patients with 
CD and 15 (17.6%) with UC had a reduction in Tt,,, a percentage significantly higher than in controls (PcO.05). 
The majority of the patients with fico reduction were in an active phase of disease (PcO.05). 
Our results suggest that there is no difference in routine PFTs between UC and CD patients, as well as between 
both these groups and normal controls. However, Tt,, abnormalities related to the degree of disease activity are 
found in patients with both UC and CD. 
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Introduction 
Pulmonary manifestations have been reported in inflamma- 
tory bowel disease (IBD), including chronic bronchial sup- 
puration in patients with ulcerative colitis (UC) (l-3), 
granulomatous lung disease (4), pulmonary vasculitis (5), 
diffuse or localized interstitial lung fibrosis (6,7), and 
bronchiectasis (8). Lung involvement usually follows the 
onset of IBD but, in some cases, respiratory manifestations 
pre-date IBD (9). Latent pulmonary involvement has 
recently been reported in a paediatric population with 
active Crohn’s disease (CD), despite the short duration of 
the disease and the absence of smoking (10). Increased 
bronchial responsiveness in IBD patients with no broncho- 
pulmonary symptoms and normal baseline lung function 
has been reported (11). Previous reports of abnormalities in 
baseline pulmonary function testing (PFT) in IBD are 
conflicting because most studies have incorporated patients 
suffering from both UC and CD diseases, which are clini- 
cally and histologically distinct (12-15). This heterogeneity 
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may explain in part the discrepancies in studies concerning 
lung abnormalities in IBD patients. 
The aim of this study was to investigate whether any 
pulmonary abnormalities could be detected in a large group 
of IBD patients by routine PFTs and whether there is any 
difference between the two IBD entities, i.e. UC and CD, or 
between subgroups within the two groups according to 
activity, severity and treatment mode. 
Subjects and Methods 
SUBJECTS 
A total of 132 patients with IBD, 47 with CD (17 female, 30 
male) of mean age 35 years, and 85 with UC (35 female, 50 
male) of mean age 40 years, both histologically confirmed, 
agreed to participate in the study and gave informed 
consent. Demographic data on the patients - their smoking 
habits, disease characteristics according to location, stage 
of activity, duration and drug treatment-are shown in 
Table 1. The location and the extent of the bowel disease 
was studied by radiological and/or endoscopical examina- 
tions. Clinical remission in patients with UC was consid- 
ered present if patients had one or two stools a day without 
blood, no fever or tachycardia, as well as haemoglobin and 
ESR level at normal or returning to normal (16). The 
activity of CD was assessed using the Crohn’s disease 
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activity index (CDAI) (17,18). Clinical remission in patients 
with CD was defined as an index score of less than 150 
(17,18). Patients who had a CDAI score higher than 150 
were classified in three stages of mild, moderate and severe 
disease (16,17). The severity of the ulcerative colitis was 
assessed primarily on the basis of clinical features using the 
criteria of Truelove and Witss (18). According to these 
criteria the severity of the disease was classified into three 
stages - mild, moderate and severe. 
None of the patients had evidence of ankylosing spond- 
ylitis or other connective tissue disease. The presence or 
absence of respiratory symptoms was not taken into 
account in the selection of patients. A control group of 36 
healthy subjects (15 female, 21 male), mean age ( * SD) 
39 f 17 years, agreed to participate in the study. None had 
a history of respiratory disease or evidence of upper or low 
respiratory infection for at least 2 months before the study. 
No significant difference in the percentage of tobacco use 
between the normal controls and the two groups of patients 
was found by chi-square test. 
PROTOCOL 
The patients and controls were studied for 2 consecutive 
days. During the first day, history, physical examination, 
posterior-anterior and lateral chest X-ray, electrocardiogra- 
phy (ECG), haematological and biochemical analyses were 
performed. During the second day, spirometry, measure- 
ment of arterial blood gases at rest and during exercise 
(ABGs), lung volumes and the carbon monoxide transfer 
factor (n,,) were performed. 
SPIROMETRY, LUNG VOLUMES, TL,, AND 
ABG MEASUREMENTS 
Spirometry, before and after inhalation of 2OOpg salbuta- 
mol, lung volumes by the helium dilution technique (19) 
and the lung transfer factor for carbon monoxide (n,,) 
corrected for the haemoglobin) by the single breath 
method (19) were performed with a computerized system 
(MasterLab, Jaeger 2.12, Germany). A positive response in 
bronchodilation was assessed in terms of an increase in the 
FEV, or FVC higher than 15% after inhalation 200 pg 
salbutamol. Predicted values were obtained from the new 
standardized lung function testing of the European Com- 
munity for Steel and Coal Luxembourg 1993 (ECSC) (19). 
All data were expressed as a percentage of the predicted 
values. Pulmonary function was regarded as being of the 
obstructive type when the FEV,/FVC ratio was lower than 
the predicted values minus two standard deviations (SD) 
and/or the presence of air trapping. Air trapping was 
defined as an increase of the residual volume (RV) and the 
RVlTLC ratio of more than 2 SD above the predicted value. 
A restrictive ventilatory syndrome and abnormal diffusing 
capacity was defined as TLC and the ZI+&VA (K,,) ratio 
reduced by more than 2 SD of the predicted values, respect- 
ively. Arterial blood gases determination was at rest in the 
upright position and during exercise using the AVL330 
analyser (Switzerland). A submaximal running exercise 
sufficient to increase the heart rate (HR) by more than 50% 
of baseline HR was defined as exercise load. The partial 
pressure of 0, and CO, (PaO, and PaCO,) was expressed 
in units of mmHg and the difference of alveolar-arterial 
partial pressure of oxygen (AaDO,) was calculated. Abnor- 
mal AaDO, was defined as an increase of more than 
15 mmHg. 
STATISTICAL ANALYSIS 
All quantitative data are expressed as mean&s~. For 
comparisons between both groups of patients and controls 
the Mann-Whitney U test was used. The difference of 
percentages between the groups was estimated using the 
chi-square test. All analyses were performed using the 
statistical package SPSS 6.0 for Windows and a P value less 
than 0.05 was considered as statistically significant. 
Results 
The mean values of PFTs and ABGs are shown in Table 2. 
No significant difference in the mean values of any par- 
ameter was found between the two groups of patients as 
well as between patients and controls. No statistically 
significant difference was found in mean values of PaO, and 
AaDO, before and after exercise. 
The number and percentages of patients and controls 
with abnormal PFTs are shown in Table 3. An increased 
percentage of abnormal PFTs among both patient groups 
was observed compared to the controls. Ten patients (21%) 
with CD (seven of those in active disease) and 15 (17.6%) 
with UC (nine in active disease) had obstructive pulmonary 
function which was not significantly different from the 
controls. Six patients (12.8%) from the CD group and 11 
(12.9%) from UC group had a positive bronchodilation 
test, but this percentage did not differ in a statistically 
significant way from that of the controls. 
TL,, reduction was found in nine (19.1%) of the patients 
with CD. The percentage of patients with CD and 
co-existing 7&, reduction was significantly different from 
that of the controls (PcO.05). A statistically significant 
difference from control subjects was found in the percent- 
age of UC patients with no0 reduction (15, 17.6%, 
PcO.05). From the group of patients in whom a TL,-, 
reduction was observed, four (9.1%) with CD and 11 
(11.8%) with UC had an abnormal AadO, during exercise. 
Further TL,, analysis showed a marginally significant 
reduction of mean value of 7t,, in patients with active 
Crohn’s disease as opposed to those whose disease was 
inactive (98 & 14.5 vs. 78 f 16.2, PcO.05, 95% Cl= 12 to 24) 
(Fig. 1). Similarly, a significant reduction of the mean value 
of fico in patients with active ulcerative colitis as com- 
pared to those with the inactive disease was observed 
(108 f 17 vs. 85 Jr 23, P<O.O5,95% Cl= 18.6 to 27) (Fig. 1). 
The majority of patients with decreased 17t,, were in the 
active phase of the disease (13115 patients with UC PcO.05 
and eight/nine patients with CD, PcO.05). 
Table 4 shows the symptoms and signs of the respiratory 
system in IBD patients and controls. An increased 
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*afpo, (at rest) 
AaDO, (after exercise) 
2 (4.3) 4 (4.7) 2 (5.5) 
3 (6.4) 8 (9.6) 1 (2.7) 
4 (8.5) 8 (9.6) 1 (2.7) 
6 (12.8) 11 (12.9) 3 (8.3) 
4 (9.1) 12 (14.1) 2 (5.5) 
7 (14.9) 12 (14.1) 3 (8.3) 
10 (21) 15 (17.6) 3 (8.5) 
6 (12.8) 11 (12.9) 3 (8.3) 
9* (19.1) 15* (17.6) 1 (2.7) 
2 (4.2) 4 (4.7) 1 (2.7) 




Crohn’s Ulcerative Control 
disease colitis 
Mean value of lung transfer factor for carbon 
monoxide (+ SD) between patients in active and in inactive 
disease and controls. 
incidence of cough and dyspnoea was observed in both IBD 
groups but did not reach a statistically significant difference 
when compared to the controls. Increased, but no signifi- 
cantly greater in statical terms, sputum production was 
found among UC patients as compared to CD patients or 
controls. Similarly, an increased incidence of abnormal 
chest sounds was observed in both groups of patients, 
especially in those with UC, but statistically this was not 
significantly different from that of the controls. In six (7%) 
patients with UC and three (6%) with CD an abnormal 
chest X-ray was found. Specifically, in two there was a 
small unilateral calcified opacity, in three unilateral pleural 
thickening with calcified plaques due to old TB pleurisy, in 
two hyperlucency of the left upper lobe and in two 
increased interstitial margins. 
Our data suggest that the reduction in TL,, is signifi- 
cantly higher in patients with an exacerbation of the disease 
than in those who are in remission (Fig. 1). This finding is 
in accordance with a recently reported study by Munck 
et al. (lo), who observed a higher prevalence of impaired 
&, among paediatric patients with active-phase Crohn’s 
disease as compared with paediatric patients in remission. 
Douglas et al. (20) reported a reduced gas transfer factor in 
16% of 44 patients with IBD, but these abnormalities did 
not appear to be related to disease activity, medication or 
any immunological variable. However, elevation of both 
FRC and RV was found in nine (20%) patients, and 
these abnormalities appear to be associated with active 
inflammatory disease. 
Reduction of ncO in 25% of patients with CD has been 
reported by Heatley and colleague (15). Reduction of &.,, 
in patients with IBD has been reported in studies performed 
by Eade et al. (21) and Bonniere et al. (22). In these studies 
the reduction of TLC0 has not correlated with the location 
or severity of inflammatory bowel disease or with the 
concurrent medication mode. Similarly, in the present study 
the reduction of Z&., did not correlate with location, 
severity or treatment mode of patients. By contrast, Pasquis 
and associates (23) found an increased functional residual 
capacity (FRC) during the active phase of the disease, 
which correlated with the Crohn’s disease severity index. 
No significant difference was found in any PFT par- The reduction of gas transfer factor indicates a damage 
ameter according to the location and the severity of the of lung parenchyma. The nature of this lung involvement 
disease (Kruskal Wallis and chi-square test). Similarly, no remains debatable. High proportions of alveolar lym- 
significant difference was found in PFTs between patients phocytes (alveolar lymphocytosis) have been reported 
treated for their underlying disease and non-treated patients among patients with CD who are free of clinical pulmonary 
(Mann-Whitney U test and chi-square test). symptoms and who have normal chest X-ray (22,24). There 
Discussion 
The main finding of this study was the marked prevalence 
of reduced ficO in patients with CD and UC, suggesting 
lung involvement. Eight out of nine patients with CD, and 
12 out of 15 with UC and TL,, reduction, exhibited a 
restrictive ventilatory syndrome according to our definition 
(Table 3). 
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TABLE 4. Incidence of respiratory symptoms in patients and in controls 
Symptoms and Crohn’s disease 









Abnormal breath sounds: 
prolong expiration 
crackles 
3 (6.4) 9 (10.6) 1 (2.7) 
6 (128) 4 (4.7) 1 (2.7) 
1 (2.1) 1 (1.2) 
1 (2.1) 9 (10.6) 1 (2.7) 
5 (10.6) 10 (11.7) 2 (5.7) 
3 (6.3) 9 (10.6) 1 (2%) 
is increasing evidence that there is an immune system 
specific to the gastrointestinal tract, and common to all 
mucosal surface (25), in which lymphocytes are sensitized to 
antigens predominantly at the intestinal mucosa. Such 
lymphocytes are localized by circulation and induce inflam- 
mation in other organs (10,22,24). It is noteworthy that 
there are some similarities, morphological and the develop- 
mental, between the colonic and the bronchial epithelium. 
Both are derived from primitive gut. The non-specific 
inflammatory changes in the bronchial epithelium are simi- 
lar to those in the colonic epithelium (26). Changes in the 
bronchial epithelium, consisting of basal cell hyperplasia, 
basement membrane thickening, submucosal inflammation, 
and an overall increase in thickness of the epithelium in 
patients with UC and co-existent bronchial suppuration has 
been reported (3). Thus, the hypothesis that the primary 
intestinal inflammation results in a secondary subclinical 
inflammation in the lungs may explain our findings. 
An increased percentage of patients with abnormal PFTs 
were observed among the patient groups (Table 3). How- 
ever, statistically this percentage was not significantly 
different from that of our normal group. The results derived 
from previous reports of pulmonary function abnormalities 
in patients with IBD are conflicting. In some studies no 
difference in PFTs between patients with IBD and a control 
group was found (13,27). Our results are in accordance with 
the study of Neilly and colleagues (27); these authors 
reported that airway obstruction was the most common 
finding affecting the patients with Crohn’s disease. How- 
ever, the indices of airways obstruction in the CD group 
were not significantly different from those obtained in age, 
sex and smoking-matched controls. Furthermore, no sig- 
nificant difference was found in the percentage of positive 
post-bronchodilation responses between patients and con- 
trols. In a recently reported study, Louis and colleague (11) 
found increased subclinical bronchial responsiveness in 
IBD patients independently of the presence of atopy. 
However, in their study the baseline lung function and 
bronchodilation test were within normal range. 
No significant differences in PFTs were found between 
treated and untreated patients. The sulphasalazine- and 
mesalazine-related adverse reactions in lung are hyper- 
sensitivity alveolitis and pneumonitis in the parenchyma 
(2829) as well as bronchiolitis obliterans (30) in the air- 
ways. Lung involvement due to the medications should be 
clearly separated from that which has been observed to 
accompany IBD. However, the distinction may be difficult 
in some cases (9). None of our patients had clinical, 
functional (PFTs) or radiological findings indicating inter- 
stitial lung disease or bronchiolitis obliterans. In accord- 
ance with our own results, most of the studies concerning 
the relationship between sulphasalazine treatment in IBD 
patients and pulmonary function abnormalities have failed 
to find any correlation (3,21,22). 
In conclusion, although routine PFTs were in the normal 
range in the majority of IBD patients, reduction of the lung 
transfer factor for carbon monoxide was found to be 
related with the active phase of the disease. The cross- 
sectional design of our study is not the best way to 
investigate groupwise differences. This limitation could be 
overcome by using a longitudinal study in which the 
patients are studied during the active and inactive phase of 
their disease. Thus, further investigation is needed to 
confirm the nature and significance of our observation. 
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